Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain. Carinae Study

Maria Casanova Espinosa, Miguel Teodoro Hernández Garcia, Juan Alfonso Soler Campos, Susana Hernández Rodriguez, Maria Jose Moreno Belmonte, Miriam Concepcion Gonzalez Pardo, Mercedes Gironella Mesa, Felipe de Arriba de la Fuente

Blood (2023) 142 (Supplement 1): 4694.

https://doi.org/10.1182/blood-2023-172708

Published: 2023

Journal Articles

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulàlia Genescà, Pere Barba, Jordi Ribera, Irene García-Cadenas, María José Moreno, Daniel Martínez-Carballeira, Anna Torrent, Pilar Martínez-Sánchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, María Teresa Artola, Marta Cervera, José González-Campos, Carlos Rodríguez, Arancha Bermúdez, Andrés Novo, Beatriz Soria, Rosa Coll, María-Luz Amigo, Aurelio López-Martínez, Rosa Fernández-Martín, Josefina Serrano, Santiago Mercadal, Antònia Cladera, Alberto Giménez-Conca, María-Jesús Peñarrubia, Eugènia Abella, Ferran Vall-llovera, Jesús-María Hernández-Rivas, Antoni Garcia-Guiñon, Juan-Miguel Bergua, Beatriz de Rueda, María-José Sánchez-Sánchez, Alfons Serrano, María Calbacho, Natalia Alonso, Jose-Ángel Méndez-Sánchez, Raimundo García-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao

Blood (2021) 137 (14): 1879–1894.

https://doi.org/10.1182/blood.2020007311

Published: 2021

Includes: Supplemental data

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Josep-Maria Ribera, Olga García, Pau Montesinos, MD PhD, Pilar Martinez, MD, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, MD, Anna Torrent, Joaquin Martinez-Lopez, MD, Santiago Mercadal, MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137489

Published: 2020

Journal Articles

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140934

Published: 2020

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Josep-Maria Ribera, MD PhD, Olga García, Pilar Martinez, MD, Pau Montesinos Fernandez, MD PhD, Blanca Boluda, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, Susana Vives, MD, Mar Tormo, MD PhD, Jesús María Hernández-Rivas, MD PhD, Joaquin Martinez-Lopez, MD PhD, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 3874.

https://doi.org/10.1182/blood-2019-125558

Published: 2019

Journal Articles

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Blood (2019) 134 (Supplement_1): 2584.

https://doi.org/10.1182/blood-2019-125683

Published: 2019

Journal Articles

Prognostic Value of Diffusion-Weighted Magnetic Resonance Imaging in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation

Elena Fernández-Poveda, Valentin Cabañas, MD, Maria José Moreno, Miguel Blanquer Blanquer, MD PhD, José M Moraleda, MD

Blood (2019) 134 (Supplement_1): 3146.

https://doi.org/10.1182/blood-2019-130804

Published: 2019

Journal Articles

Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial

Blood (2019) 134 (Supplement_1): 826.

https://doi.org/10.1182/blood-2019-123613

Published: 2019

Journal Articles

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Blood (2018) 132 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2018-99-114559

Published: 2018

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

Blood (2017) 130 (Supplement 1): 2017.

https://doi.org/10.1182/blood.V130.Suppl_1.2017.2017

Published: 2017

Journal Articles

Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials

Blood (2017) 130 (Supplement 1): 1323.

https://doi.org/10.1182/blood.V130.Suppl_1.1323.1323

Published: 2017

Journal Articles

Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalitions (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group

Blood (2016) 128 (22): 1602.

https://doi.org/10.1182/blood.V128.22.1602.1602

Published: 2016

Journal Articles

Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain

Blood (2015) 126 (23): 2723.

https://doi.org/10.1182/blood.V126.23.2723.2723

Published: 2015

Journal Articles

Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance

Blood (2014) 124 (21): 25.

https://doi.org/10.1182/blood.V124.21.25.25

Published: 2014

Journal Articles

Different Prognosis According to Subtype-Oriented Protocols in Elderly Patients with Acute Lymphoblastic Leukemia (ALL). Comparison of Three Prospective Parallel Trials from the Pethema Group

Blood (2013) 122 (21): 3869.

https://doi.org/10.1182/blood.V122.21.3869.3869

Published: 2013

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.

Blood (2009) 114 (22): 322.

https://doi.org/10.1182/blood.V114.22.322.322

Published: 2009

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial.

Blood (2008) 112 (11): 3291.

https://doi.org/10.1182/blood.V112.11.3291.3291

Published: 2008

Journal Articles

VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients

Enrique Colado, MD, Maria-Victoria Mateos, MD, PhD, Maria-Jose Moreno, MD, Felipe de Arriba, MD, Javier de la Rubia, MD, Juan José Lahuerta, MD, PhD, Pastora Iniesta, MD, Maria Cruz Viguria, MD, Ana Pilar Gonzalez, MD, Ramón García-Sanz, MD, PhD, Juan Olazabal, MD, Jesús F San Miguel

Blood (2008) 112 (11): 3694.

https://doi.org/10.1182/blood.V112.11.3694.3694

Published: 2008

Journal Articles

Specific Intensive Chemotherapy Plus Rituximab for Advanced Burkitt’s Lymphoma or Leukemia in HIV-Positive and Negative Adult Patients.

Josep-Maria Ribera, PhD, Albert Oriol, MD, Jordi Esteve, Juan Bergua, Santiago Larregla, Salut Brunet, Santiago delPotro, Lourdes Escoda, Maria-Jose Moreno-Rico, Javier Lopez Jimenez, Evarist Feliu

Blood (2007) 110 (11): 3448.

https://doi.org/10.1182/blood.V110.11.3448.3448

Published: 2007

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Classical Risk Factors and Minimal Residual Disease (MRD). Interim Results of the PETHEMA ALL-AR-03 Trial.

Blood (2006) 108 (11): 1872.

https://doi.org/10.1182/blood.V108.11.1872.1872

Published: 2006

NARROW

Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain. Carinae Study

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Prognostic Value of Diffusion-Weighted Magnetic Resonance Imaging in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials

Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalitions (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group

Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain

Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance

Different Prognosis According to Subtype-Oriented Protocols in Elderly Patients with Acute Lymphoblastic Leukemia (ALL). Comparison of Three Prospective Parallel Trials from the Pethema Group

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial.

VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients

Specific Intensive Chemotherapy Plus Rituximab for Advanced Burkitt’s Lymphoma or Leukemia in HIV-Positive and Negative Adult Patients.

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Classical Risk Factors and Minimal Residual Disease (MRD). Interim Results of the PETHEMA ALL-AR-03 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only